The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Antibodies to watch in 2019
Open accessAbstract
For the past 10 years, the annual 'Antibodies to watch' articles have provided updates on key events in the late-stage development of antibody therapeutics, such as first regulatory review or approval, that occurred in the year before publication or were anticipated to occur during the year of publication. To commemorate the 10th anniversary of the article series and to celebrate the 2018 Nobel Prizes in Chemistry and in Physiology or Medicine, which were given for work that is highly relevant to antibody therapeutics research and development, we expanded the scope of the data presented to include an overview of all commercial clinical development of antibody therapeutics and approval success rates for this class of molecules. Our data indicate that: 1) antibody therapeutics are entering clinical study, and being approved, in record numbers; 2) the commercial pipeline is robust, with over 570 antibody therapeutics at various clinical phases, including 62 in late-stage clinical studies; and 3) Phase 1 to approval success rates are favorable, ranging from 17-25%, depending on the therapeutic area (cancer vs. non-cancer). In 2018, a record number (12) of antibodies (erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), burosumab (Crysvita), lanadelumab (Takhzyro), caplacizumab (Cablivi), mogamulizumab (Poteligeo), moxetumomab pasudodox (Lumoxiti), cemiplimab (Libtayo), ibalizumab (Trogarzo), tildrakizumab (Ilumetri, Ilumya), emapalumab (Gamifant)) that treat a wide variety of diseases were granted a first approval in either the European Union (EU) or United States (US). As of November 2018, 4 antibody therapeutics (sacituzumab govitecan, ravulizumab, risankizumab, romosozumab) were being considered for their first marketing approval in the EU or US, and an additional 3 antibody therapeutics developed by Chinese companies (tislelizumab, sintilimab, camrelizumab) were in regulatory review in China. In addition, our data show that 3 product candidates (leronlimab, brolucizumab, polatuzumab vedotin) may enter regulatory review by the end of 2018, and at least 12 (eptinezumab, teprotumumab, crizanlizumab, satralizumab, tanezumab, isatuximab, spartalizumab, MOR208, oportuzumab monatox, TSR-042, enfortumab vedotin, ublituximab) may enter regulatory review in 2019. Finally, we found that approximately half (18 of 33) of the late-stage pipeline of antibody therapeutics for cancer are immune checkpoint modulators or antibody-drug conjugates. Of these, 7 (tremelimumab, spartalizumab, BCD-100, omburtamab, mirvetuximab soravtansine, trastuzumab duocarmazine, and depatuxizumab mafodotin) are being evaluated in clinical studies with primary completion dates in late 2018 and in 2019, and are thus 'antibodies to watch'. We look forward to documenting progress made with these and other 'antibodies to watch' in the next installment of this article series.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Searching for Peptide Ligands with an Epitope Library
Scott, J. K., & Smith, G. P. (1990) · Science · doi:10.1126/science.1696028 · Cited by 2,084
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501 · cited 1×
“Sickle cell disease, caused by mutations in the gene encoding hemoglobin subunit β, is characterized by production of red blood cells that are misshapen, prone to hemolysis and can occlude the vasculature, causing pain.(69) P-selectin found on endothelial cells and platelets participates in cell-cell interactions that…”
BackgroundMonoclonal antibody successes in the clinic
Reichert, J. M., Rosensweig, C. J., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 733
Self-citationGordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31713-6 · Cited by 678
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
Dodick, D. W., Silberstein, S. D., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2018) · JAMA · doi:10.1001/jama.2018.4853 · Cited by 562
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2484 · Cited by 498
Fang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 489
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Insogna, K. L., Briot, K., Imel, E. A., Kamenický, P., Ruppe, M. D., Portale, A. A., Weber, T., Pitukcheewanont, P., Cheong, H. I., Jan de Beur, S., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3475 · Cited by 343
Morgensztern, D., Besse, B., Greillier, L., Santana-Davila, R., Ready, N., Hann, C. L., Glisson, B. S., Farago, A. F., Dowlati, A., Rudin, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1133 · Cited by 326
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 290
Nerve Growth Factor and Pain Mechanisms
Denk, F., Bennett, D. L., & McMahon, S. B. (2017) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-072116-031121 · Cited by 257
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Kreitman, R. J., Dearden, C., Zinzani, P. L., Delgado, J., Karlin, L., Robak, T., Gladstone, D. E., le Coutre, P., Dietrich, S., Gotic, M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0210-1 · Cited by 251
Reichert, J. M. (2017) · mAbs · doi:10.1080/19420862.2016.1269580 · Cited by 244
Self-citationKaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1415671 · Cited by 244
Self-citationAntibody-based therapeutics to watch in 2011
Reichert, J. M. (2011) · mAbs · doi:10.4161/mabs.3.1.13895 · Cited by 236
Self-citationPhase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Emu, B., Fessel, J., Schrader, S., Kumar, P., Richmond, G., Win, S., Weinheimer, S., Marsolais, C., & Lewis, S. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711460 · Cited by 227
Marketing approval of mogamulizumab: A triumph for glyco-engineering
Beck, A., & Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.20996 · Cited by 211
Self-citationHuang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 203
Reichert, J. M. (2016) · mAbs · doi:10.1080/19420862.2015.1125583 · Cited by 175
Self-citationDrugs derived from phage display: From candidate identification to clinical practice
Nixon, A. E., Sexton, D. J., & Ladner, R. C. (2014) · mAbs · doi:10.4161/mabs.27240 · Cited by 167
Mo, H., Huang, J., Xu, J., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Wang, X., Xu, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0100-3 · Cited by 159
Reichert, J. M. (2014) · mAbs · doi:10.4161/19420862.2015.988944 · Cited by 156
Self-citationKutlar, A., Kanter, J., Liles, D., Alvarez, O. A., Cançado, R. D., Friedrisch, J. R., Knight‐Madden, J., Bruederle, A., Shi, M. M., Zhu, Z., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25308 · Cited by 129
Which are the antibodies to watch in 2013?
Reichert, J. M. (2013) · mAbs · doi:10.4161/mabs.22976 · Cited by 128
Self-citationReichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 106
Self-citationReichert, J. M. (2014) · mAbs · doi:10.4161/mabs.27333 · Cited by 96
Self-citationNext generation immune-checkpoints for cancer therapy
Donini, C., D’Ambrosio, L., Grignani, G., Aglietta, M., & Sangiolo, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.79 · Cited by 79
Blauvelt, A., Reich, K., Papp, K. A., Kimball, A. B., Gooderham, M., Tyring, S. K., Sinclair, R. D., Thaçi, D., Li, Q., Cichanowitz, N., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16724 · Cited by 76
Richardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 74
Kellner, C., Zhukovsky, E. A., Pötzke, A., Brüggemann, M., Schrauder, A., Schrappe, M., Kneba, M., Repp, R., Humpe, A., Gramatzki, M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.373 · Cited by 43
CCR5: Established paradigms and new frontiers for a ‘celebrity’ chemokine receptor
Scurci, I., Martins, E., & Hartley, O. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.018 · Cited by 29
Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society
Zhang, H., Deng, M., Lin, P., Liu, J., Liu, C., Strohl, W. R., Wang, S., & Ho, M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby009 · Cited by 17
Zhou, C., Gao, G., Wu, F., Chen, X., Li, W., Xiong, A., Su, C., Cai, W., Ren, S., Jiang, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e21017 · Cited by 15
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M. (2020) · mAbs · doi:10.1080/19420862.2019.1703531 · Cited by 429
Self-citation
Metadata
- Authors
- Kaplon, H., & Reichert, J. M.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2018-12-22
- Volume
- 11
- Issue
- 2
- Pages
- 219-238
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2915483287
- Cited by
- 434
- References
- 39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.